Elixiron Immunotherapeutics
Latest round
- Series A
Last raised
- Aug 2021
Total raised
- $27M
Investors
- 7
About Elixiron Immunotherapeutics
Established in 2017 and based in Shanghai, China, Elixiron Immunotherapeutics is dedicated to addressing unmet clinical needs through the development of novel immunotherapeutic drugs. The company was founded by Dr. Xiaohua Duan. With a focus on advancing therapies for conditions such as vitiligo and Alzheimer's disease, Elixiron has established partnerships with global entities to enhance its research and development capabilities.S. FDA for its products targeting Hemophagocytic Lymphohistiocytosis (HLH) and Idiopathic Pulmonary Fibrosis (IPF). The company's product pipeline includes EI-001, an IFN? antibody currently in Phase 1b/2 clinical development for the treatment of vitiligo, and EI-1071, a CSF-1R targeted small molecule drug in Phase 2 clinical trials aimed at treating Alzheimer's disease. The company's services are centered around the research, development, and clinical advancement of these innovative immunotherapeutic agents, with the goal of providing new treatment options for patients suffering from autoimmune and neurodegenerative disorders.
Who invested in Elixiron Immunotherapeutics
7 investors across 1 round
See all investors in Elixiron Immunotherapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Aug 16, 2021
Amount
$27M
Investors
Questions about Elixiron Immunotherapeutics
Who invested in Elixiron Immunotherapeutics?
Elixiron Immunotherapeutics has 7 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Elixiron Immunotherapeutics raised?
Elixiron Immunotherapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Elixiron Immunotherapeutics last raise money?
Elixiron Immunotherapeutics's most recent round on record is a Series A, in Aug 2021.
What does Elixiron Immunotherapeutics do?
Established in 2017 and based in Shanghai, China, Elixiron Immunotherapeutics is dedicated to addressing unmet clinical needs through the development of novel immunotherapeutic drugs.
Where is Elixiron Immunotherapeutics headquartered?
Elixiron Immunotherapeutics is headquartered in Shanghai, China.
Which VCs invest in companies like Elixiron Immunotherapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Elixiron Immunotherapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Elixiron Immunotherapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.